Michael Barbella, Managing Editor04.04.24
NeurAxis Inc. has appointed Timothy Henrichs as chief financial officer (CFO). As part of his appointment, Henrichs has resigned as an independent board director.
"We are thrilled to announce Tim as the new chief financial officer of NeurAxis,” NeurAxis President/CEO Brian Carrico said. “His experience will be highly valuable as we continue to move forward with our strategic commercialization activities in 2024 and beyond.”
Henrichs has more than 20 years of global leadership experience in several industries, including healthcare, home improvement, retail, software, and education. Most recently, Henrichs was CFO of Renovo Home Partners (since 2022). He also served as executive vice president and CFO of Follett Corporation from 2008 to 2022; and global controller of GE’s Healthcare Clinical Systems division, which manufactures and distributes medical devices to the ultrasound, patient monitoring, and anesthesiology markets (2005-2008). In addition, Henrichs held leadership positions at Federal Signal Corporation and Ernst & Young LLP.
Henrichs earned a bachelor’s degree in accounting from the University of Notre Dame and is a certified public accountant with an inactive license in the State of Illinois.
“I am excited to be joining NeurAxis as its chief financial officer,” Henrichs stated. “I look forward to being part of the team and the mission to improve patient outcomes in the field of disorders of the gut-brain interaction.”
NeurAxis Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis advances science and leverages evidence-based medicine to drive adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is cleared by the U.S. Food and Drug Administration for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.
"We are thrilled to announce Tim as the new chief financial officer of NeurAxis,” NeurAxis President/CEO Brian Carrico said. “His experience will be highly valuable as we continue to move forward with our strategic commercialization activities in 2024 and beyond.”
Henrichs has more than 20 years of global leadership experience in several industries, including healthcare, home improvement, retail, software, and education. Most recently, Henrichs was CFO of Renovo Home Partners (since 2022). He also served as executive vice president and CFO of Follett Corporation from 2008 to 2022; and global controller of GE’s Healthcare Clinical Systems division, which manufactures and distributes medical devices to the ultrasound, patient monitoring, and anesthesiology markets (2005-2008). In addition, Henrichs held leadership positions at Federal Signal Corporation and Ernst & Young LLP.
Henrichs earned a bachelor’s degree in accounting from the University of Notre Dame and is a certified public accountant with an inactive license in the State of Illinois.
“I am excited to be joining NeurAxis as its chief financial officer,” Henrichs stated. “I look forward to being part of the team and the mission to improve patient outcomes in the field of disorders of the gut-brain interaction.”
NeurAxis Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis advances science and leverages evidence-based medicine to drive adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is cleared by the U.S. Food and Drug Administration for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.